Melcura

MelCura is a clinical-stage biotechnology company based in Tübingen, Germany, specializing in personalized cancer vaccines. A spin-off from the University of Tübingen, the company utilizes a proprietary immunopeptidomics platform to identify patient-specific tumor antigens via mass spectrometry. Its lead program, MelVac, is a personalized peptide-based vaccine currently undergoing Phase 1 clinical trials for the treatment of malignant melanoma. MelCura's technology aims to trigger a highly specific immune response against cancer cells while minimizing off-target effects. The company leverages deep expertise in HLA ligandome analysis to develop truly individualized therapies. By focusing on the unique molecular signature of each patient's tumor, MelCura is advancing the field of precision oncology.